AwardedCzechiaGoodsCZK 9,877,000
Imunoglobuliny SCIG_V. - CUVITRU
- Published
- Published 16 April 2026
- Deadline
- Closed 19 May 2026
Overview
The Institut klinické a experimentální medicíny has awarded a contract for the supply of human immunoglobulin (Cuvitru) for subcutaneous immunoglobulin therapy (SCIG) treatment to Takeda Pharmaceuticals Czech Republic s.r.o. The contract, valued at 9,876,900 CZK, was awarded on 22 May 2026 for treatment of patients in approved indications as per current product information.
Key details
- Country
- Czechia
- Status
- Awarded
- Category
- Goods
- Estimated value
- CZK 9,877,000
- Procedure
- Open
- Published
- 16 April 2026
- Deadline
- Closed
Immunoglobulins
Award outcome
- Awarded value
- CZK 9,876,900
- Award date
- 22 May 2026
- Contract period
- — → 1 May 2030
- Takeda Pharmaceuticals Czech Republic s.r.o.
Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.
Notice history
Every published notice in this contracting process, newest first.
Contract Award Notice
18 June 2026
Contract Notice
16 April 2026
Contracting authority
Institut klinické a experimentální medicíny
Procuring entityPraha, Czechia
Authority website ↗
Get the full picture
AI analysis, bid scoring, and expert strategy for this tender
Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.
See which competitors are winning the contracts you're chasing.
15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.